See FY25 operating cash flow $280M-$310M.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 15c
- Amneal Pharmaceuticals sees FY25 adjusted EPS 65c-75c, consensus 71c
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
- Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals